These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 28369378)

  • 21. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
    Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
    Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MBNL1 overexpression is not sufficient to rescue the phenotypes in a mouse model of RNA toxicity.
    Yadava RS; Kim YK; Mandal M; Mahadevan K; Gladman JT; Yu Q; Mahadevan MS
    Hum Mol Genet; 2019 Jul; 28(14):2330-2338. PubMed ID: 30997488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2.
    Carpentier C; Ghanem D; Fernandez-Gomez FJ; Jumeau F; Philippe JV; Freyermuth F; Labudeck A; Eddarkaoui S; Dhaenens CM; Holt I; Behm-Ansmant I; Marmier-Gourrier N; Branlant C; Charlet-Berguerand N; Marie J; Schraen-Maschke S; Buée L; Sergeant N; Caillet-Boudin ML
    Biochim Biophys Acta; 2014 Apr; 1842(4):654-64. PubMed ID: 24440524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
    Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
    Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.
    Azotla-Vilchis CN; Sanchez-Celis D; Agonizantes-Juárez LE; Suárez-Sánchez R; Hernández-Hernández JM; Peña J; Vázquez-Santillán K; Leyva-García N; Ortega A; Maldonado V; Rangel C; Magaña JJ; Cisneros B; Hernández-Hernández O
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
    Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
    Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.
    Lin X; Miller JW; Mankodi A; Kanadia RN; Yuan Y; Moxley RT; Swanson MS; Thornton CA
    Hum Mol Genet; 2006 Jul; 15(13):2087-97. PubMed ID: 16717059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.
    Chau A; Kalsotra A
    Dev Dyn; 2015 Mar; 244(3):377-90. PubMed ID: 25504326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).
    Gladman JT; Mandal M; Srinivasan V; Mahadevan MS
    PLoS One; 2013; 8(9):e72907. PubMed ID: 24039817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.
    Fardaei M; Larkin K; Brook JD; Hamshere MG
    Nucleic Acids Res; 2001 Jul; 29(13):2766-71. PubMed ID: 11433021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1.
    Nutter CA; Kidd BM; Carter HA; Hamel JI; Mackie PM; Kumbkarni N; Davenport ML; Tuyn DM; Gopinath A; Creigh PD; Sznajder ŁJ; Wang ET; Ranum LPW; Khoshbouei H; Day JW; Sampson JB; Prokop S; Swanson MS
    Brain; 2023 Oct; 146(10):4217-4232. PubMed ID: 37143315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FISH Protocol for Myotonic Dystrophy Type 1 Cells.
    Klein AF; Arandel L; Marie J; Furling D
    Methods Mol Biol; 2020; 2056():203-215. PubMed ID: 31586350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.
    Dansithong W; Paul S; Comai L; Reddy S
    J Biol Chem; 2005 Feb; 280(7):5773-80. PubMed ID: 15546872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.
    Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Klinck R; Rocheleau L; Pelchat M; Chabot B; Jasmin BJ; Côté J
    PLoS Genet; 2016 Jan; 12(1):e1005827. PubMed ID: 26824521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats.
    Laurent FX; Sureau A; Klein AF; Trouslard F; Gasnier E; Furling D; Marie J
    Nucleic Acids Res; 2012 Apr; 40(7):3159-71. PubMed ID: 22156369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a
    Chakraborty M; Sellier C; Ney M; Pascal V; Charlet-Berguerand N; Artero R; Llamusi B
    Dis Model Mech; 2018 Apr; 11(4):. PubMed ID: 29592894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy.
    Chen G; Masuda A; Konishi H; Ohkawara B; Ito M; Kinoshita M; Kiyama H; Matsuura T; Ohno K
    Sci Rep; 2016 Apr; 6():25317. PubMed ID: 27126921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.
    Kanadia RN; Shin J; Yuan Y; Beattie SG; Wheeler TM; Thornton CA; Swanson MS
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11748-53. PubMed ID: 16864772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
    Wojciechowska M; Sobczak K; Kozlowski P; Sedehizadeh S; Wojtkowiak-Szlachcic A; Czubak K; Markus R; Lusakowska A; Kaminska A; Brook JD
    Sci Rep; 2018 Apr; 8(1):5885. PubMed ID: 29651162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.
    Mahadevan MS; Yadava RS; Yu Q; Balijepalli S; Frenzel-McCardell CD; Bourne TD; Phillips LH
    Nat Genet; 2006 Sep; 38(9):1066-70. PubMed ID: 16878132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.